Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma

Hong Kong Medical Journal

Volumn 10, Issue 2, 2004, Pages 77-83

  Ma, S Y ^a   Lie, A K W ^a   Au, W Y ^a   Chim, C S ^a   Kwong, Y L ^a   Liang, R ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Multiple myeloma; Myeloablative agents; Transplantation

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CHIMERA; CHINESE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTRECTOMY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HONG KONG; HUMAN; LYMPHOCYTE; MALE; MORTALITY; MULTIPLE MYELOMA; RELAPSE; REMISSION; STOMACH CARCINOMA; SURVIVAL RATE; TOXICITY; VIRUS INFECTION; WHOLE BODY RADIATION;

ADULT; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HONG KONG; HUMANS; LIVING DONORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 1842713262     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
2. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-64.
3. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997;34(1 Suppl 1):61S-66S.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
5. Fermand JP, Brechignac S. The role of autologous stem cell transplantation in the management of multiple myeloma. Pathol Biol (Paris) 1999;47:199-202.
6. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
7. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248-53.
8. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991;325:1267-73.
9. Cavo M, Benni M, Cirio TM, Gozzetti A, Tura S. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. Stem Cells 1995;13(Suppl 2): 126S-131S.
10. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4711-8.
11. Goldschmidt H, Egerer G, Ho AD. Autologous and allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2000;25(Suppl 2):25S-26S.
12. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-22.
13. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17:208-15.
14. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996;87:1196-8.
15. Verdonck L, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800-1.
16. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031-7.
17. Orsini E, Alyea EP, Chillemi A, et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant 2000;6:375-86.
18. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179-84.
19. Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Huntingt) 1999;13:621-8,631,635-8,641.
20. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-24.
21. Childs RW. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J 2000;6:179-87.
22. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
23. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
24. Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. Curr Opin Oncol 2001;13:95-100.
25. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295-303.
26. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574-9.
27. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
28. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
29. Nuckols JD, Rasheed BK, McGlennen RC, Bigner SH, Stenzel TT. Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit. Am J Clin Pathol 2000;113:135-40.
30. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000;96:3995-6.
31. Singhal S, Mehta J. Treatment of relapsed and refractory multiple myeloma. Curr Treat Options Oncol 2003;4:229-37.
32. Badros A, Tricot G, Toor A, et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002;42:205-9.
33. Maciej Zaucha J, Mielcarek M, Takatu A, et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol 2002;119:740-50.
34. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001;98:3584-8.
35. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998;29:301-13.
36. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000;26:251-5.